We evaluated the microbiological diagnosis in 14 patients with epidemiological and clinical suspicion of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) attended in a non-endemic area between June 2015 and January 2017. While no MERS-CoV was detected, other respiratory viruses were identified in 12 cases and Mycoplasma pneumoniae in 1 case.
Background
The Middle East Respiratory Syndrome Coronavirus (MERSCoV) is a novel coronavirus first described in the Arabian Peninsula in 2012. 1 Humans may become infected through contact with contaminated respiratory secretions from infected patients or animals (mainly dromedaries). Although human-tohuman transmission of the virus is low, MERS-CoV has been known to spread from ill people to others through close contact such as caring for or living with an infected person. Thus, transmission of MERS-CoV is more likely to occur in healthcare facilities, 2 with most of the cases reported having been associated with nosocomial outbreaks. 3 As of July 2017, 2040 laboratory- between June 2015 and January 2017. These guidances specify that any patient with an epidemiologic risk and severe ore miler respiratory illness should be considered as a patient under investigation for MERS-CoV. According to the protocol established by the Public Health Agency of Catalonia any clinical suspicion of MERS-CoV should be analysed in our hospital, which is the reference centre for MERS-CoV diagnosis in the region of Catalonia (North Eastern Spain) holding a laboratory with biosafety level II and providing rapid results 24 h a day, 7 days a week. These patients remained in an isolation type III room until laboratory results became available. Respiratory samples (nasopharyngeal swabs and whenever possible a sputum) were collected and sent to the Microbiology laboratory. For the detection of MERSCoV, RNA extraction of inactivated samples was performed using an automated system (QiaSymphony; Quiagen, Hilden, Germany) followed by real-time reverse-transcription polymerase chain reaction (RT-PCR) targeting upstream of the upE gene, encoding protein E, as described previously.
9,10 Synthetic RNA standards were used as the positive control. Additionally, all nasopharyngeal swabs samples were tested with a multiplex PCR system (FilmArray Respiratory Pannel, BioMérieux, Marcy l'Etoile, France). This is an integrated and automated system which allows the detection of 17 viral agents (influenza viruses A and B, parainfluenza viruses 1-4, respiratory syncytial virus, adenovirus, bocavirus, coronaviruses HKU1, NL63, 229E and OC43, metapneumovirus, human rhinovirus/enterovirus) and 3 bacterial agents (Bordetella pertussis, Chlamydophila pnuemoniae and Mycoplasma pneumoniae) in 1 h. All tests performed in the patients in this article were part of the routine clinical assessment at Hospital Clínic.
Results
A total of 14 patients fulfilled the definition of MERS-CoV suspected case during the study period. The median age of the patients was 30 years (interquartile range: 24-65), seven (50%) were males and seven (50%) were females. All the patients resided in the Middle East except for patient 13 who had been in Singapore when there was an alert for prevention of transmission of MERS-CoV due to the outbreak in the Republic of Korea. 11 All patients presented respiratory signs or symptoms. Patients 1-11 presented milder respiratory illness (cough, odynophagia or dyspnoea) and patients 12-14 presented pneumonia based on radiological evidence (Table 1) . Real-time RT-PCR for the detection of MERS-CoV was performed in nasopharyngeal swab samples of all the patients and additionally from a sputum sample in patients 10, 12 and 14. All the samples tested negative for the detection of MERS-CoV. However, in 13 cases a respiratory pathogen was identified performing FilmArray multiplex PCR of the nasopharyngeal swabs. A respiratory virus was identified as the causative agent in 12 cases and M. pneumoniae was identified as the causative agent in 1 case (Table 1) .
Discussion
Although MERS-CoV does not seem to have an efficient humanto-human transmission, the high mortality rate of the virus and the fact that most of the cases have been related to healthcareassociated outbreaks reported in the Middle East and also in nonendemic areas from imported cases, makes necessary that potential new imported cases of MERS-CoV are early detected and isolated as soon as possible. Since the symptoms of MERS-CoV are nonspecific and can be confused with infections due to other respiratory pathogens, the presence of other respiratory agents should also be investigated in patients with clinical suspicion of MERSCoV. All the patients in the present study were negative for MERS-CoV, but the additional rapid testing for respiratory pathogens revealed the aetiological agent in most of the cases. This information allowed better patient management with rapid implementation of treatment and prevention and control measures. Previous studies 12 have shown that lower respiratory tract specimens contain higher viral loads and are more sensitive to virus detection, although upper respiratory tract specimens remain important for diagnosis and are more frequently available. 13 The fact that all suspected cases were analysed in the ref-
erence laboratory underscores the importance of good quality sampling for respiratory tract infections with unusual location for a more sensitive approach. Our results are in agreement with previous studies evaluating respiratory pathogens among pilgrims returning from an endemic area.
14,15 However, our group of patients is heterogeneous not restricted to pilgrims and with patients returning from different endemic areas. Our study supports a comprehensive evaluation of respiratory agents in addition to MERS-CoV in patients with epidemiological and clinical suspicion of MERS-CoV infection coming to non-endemic areas.
Conclusions
Patients with respiratory symptoms returning from endemic MERS-CoV areas should be urgently screened for the possible presence of MERS-CoV. Additionally, it is of critical importance to early rule out other possible respiratory agents to avoid their transmission, prevent potential outbreaks and provide adequate patient management.
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